Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Annals of oncology : official journal of the European Society for Medical Oncology

Volumn 28, Issue 5, 2017, Pages 1130-1136

  Lee, J H ^a,b   Long, G V ^a,b   Boyd, S ^a   Lo, S ^a   Menzies, A M ^a,b   Tembe, V ^b   Guminski, A ^a,b   Jakrot, V ^a,b   Scolyer, R A ^b   Mann, G J ^a,b   Kefford, R F ^a,b   Carlino, M S ^a,b   Rizos, H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

Author keywords

biomarkers; circulating tumour DNA; immunotherapy; melanoma; PD1 antibodies

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CIRCULATING TUMOR DNA; IPILIMUMAB; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOLOGY; MALE; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECOND CANCER;

AGED; ANTIBODIES, ANTI-IDIOTYPIC; BIOMARKERS, TUMOR; CIRCULATING TUMOR DNA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85025463481     PISSN: None     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx026     Document Type: Article

References (0)